Physician profile
James Lieber
NPI 1083690283
$1,535.69
in general payments reported to CMS, 2019-2025
29 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $63.74 · 2021: $315 · 2022: $135 · 2023: $190 · 2024: $260 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $226.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $189.31 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $139.85 | 2022-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $133.86 | 2021-2024 | |
| Pfizer INC. | $103.58 | 2019-2025 | |
| Astellas Pharma US INC | $85.28 | 2019-2024 | Veozah |
| Abbott Laboratories | $64.14 | 2021-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $60.96 | 2019-2024 | Farxiga |
| Amgen INC. | $60.21 | 2023-2025 | Repatha, Otezla, Otezla |
| Mannkind Corporation | $50.08 | 2021 | |
| Therapeuticsmd, INC. | $43.55 | 2019 | |
| Exact Sciences Corporation | $37.79 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $36.99 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $33.54 | 2019-2023 | |
| Boston Scientific Corporation | $26.76 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $23.37 | 2023 | Urolift |
| Nevro Corp. | $22.82 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.91 | 2025 | Jardiance |
| Seqirus USA INC | $20.12 | 2025 | Flucelvax, Fluad |
| Vanda Pharmaceuticals INC. | $19.10 | 2025 | Fanapt |
| Eisai INC. | $17.82 | 2025 | |
| Sumitomo Pharma America, INC. | $17.81 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $16.99 | 2021 | |
| Ibsa Pharma INC. | $16.51 | 2021 | |
| Amarin Pharma, INC. | $15.65 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.10 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $12.88 | 2023 | Quviviq |
| Lucid Diagnostics INC. | $12.68 | 2022 | |
| Allergan, INC. | $12.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lieber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.